Find a Health Care Professional / Researcher

Christopher Karp, MD

Appointment

Gunnar Esiason/Cincinnati Bell Chair; Director, Division of Molecular Immunology; Professor of Pediatrics; Associate Director, Graduate Program in Immunobiology; Director, Cystic Fibrosis Research Center

Email

chris.karp@cchmc.org

Phone

513-636-7608

Fax

513-636-5355

Credentials

BA:summa cum laude, with high honors in Philosophy, Brandeis University, Waltham, MA, 1978

MD: University of North Carolina School of Medicine, Chapel Hill, NC, 1986

Internal Medicine: Rhode Island Hospital, Brown University, 1986-1987.

Internal Medicine: Georgetown University Hospital, Georgetown University, 1987-1989.

NRSA Fellow: Laboratory of Parasitic Diseases, NIAID, 1989-1992.

Fellow in Infectious Diseases: Johns Hopkins University School of Medicine, 1992-1993.

Diplomate of the National Board of Medical Examiners, 1987

Diplomate in Internal Medicine, American Board of Internal Medicine, 1989

Diplomate in Infectious Disease, American Board of Internal Medicine, 1994

Certificate of Knowledge in Tropical Medicine and Travelers' Health, ASTMH, 1995

Awards and Honors

Phi Beta Kappa, Brandeis University, 1978
Summa cum laude, Brandeis University, 1978
High honors in philosophy, Brandeis University, 1978
John Motley Morehead Fellow in Medicine, University of North Carolina, 1982-86
Medical School Merit Award, University of North Carolina, 1985
NRSA Award (individual), NIAID, 1989-92
Sandoz Clinician Scientist Award, Johns Hopkins University, 1994
Fellow of the Infectious Diseases Society of America, 1999
Faculty of 1000, 2002
Member, American Society of Clinical Investigation, 2003
Gunnar Esisason/Cincinnati Bell Professorship, 2005

Research

The Karp lab focuses on understanding the molecular mechanisms underlying regulation and dysregulation of inflammatory responses in human infectious, autoimmune and genetic diseases. Interrelated, ongoing areas of study include:

The molecular mechanisms underlying dysregulation of pulmonary inflammatory responses in cystic fibrosis;
Modifier genes for cystic fibrosis lung disease;
Mechanisms of inflammation resolution: lipoxin and resolvin biology;
Immune counter-regulation in leishmaniasis;
In vivo regulation of IL-10 production;
Biology and control of Toll-like receptor-driven signaling pathways in health and disease;
Ebola virus pathogenesis and therapy.

Lab Members

Leah Flick, BA, Lab Manager
Aurelien Trompette, BA, Research Assistant
Jennifer Haky, Research Assistant
Rajat Madan, MD; PhD candidate
YuanYuan Gu, MD; PhD candidate
Jessica Allen, PhD candidate
Senad Divanovic, PhD; Post-Doctoral Fellow
Lisa Petiniot, MD, Post-Doctoral Fellow (Rheumatology)
Brad Pasternak, MD, Post-Doctoral Fellow (Gastroenterology
Naonori Uozumi, MD, PhD, Visiting Scientist

Research Grants and Contracts

National Institutes of Health, R01. (HL079312)
4/2005-2/2010
Lipid mediators and dysregulated inflammation in CF.

National Institutes of Health, R01. (AI057992).
3/2005-2/2009
Role of regulatory T cells in leishmania infection.

National Institutes of Health, R01. (AI075159)
7/2007- Regulation of Toll-like Receptor Signaling and innate immunity by RP105.

Sandler Program for Asthma Research
Senior Investigator Award
7/2006-6/2009
The role of aeroallergen mimics of TLR complex proteins in asthma pathogenesis.

National Institutes of Health, R01 (DA013324) (D. Thomas PI)
8/2004-7/2009
Hepatitis C Pathogenesis and the Human Genome.

National Institutes of Health, P30 (AR047363) (S. Thompson, PI)
7/2006-6/2008
Pilot and Feasibility Grant: Modulation of tissue inflammation by RP105/TLR4.

Cystic Fibrosis Foundation RDP Center Grant
(Component II)
9/2005-8/2007

Cystic Fibrosis Foundation RDP Center Pilot Grant
12/2006-11/2007
Biology of modifier genes for CF lung disease

Cystic Fibrosis Foundation (KARP06DDSO)
1/2007-12/2009
Anti-Inflammatory Lipid Mediator Therapy for Cystic Fibrosis.

Publications, Most Recent

Find Christopher Karp's most recent publications as listed by PubMed.

Byrnes AA, Li DY, Park K, Thompson D, Mocilnikar C, Mohan P, Molleston JP, Narkewicz M, Zhou H, Wolf SF, Schwarz KB, Karp CL. (2006) Modulation of the IL-12/IFN-{gamma} axis by IFN-{alpha} therapy for hepatitis C.J Leukoc Biol.
Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA. (2006) An adenoviral vector for probing promoter activity in primary immune cells.J Immunol Methods 311:19-30.
Atabani SF, Thio CL, Divanovic S, Trompette A, Belkaid Y, Thomas DL, Karp CL. (2005) Association of CTLA4 polymorphism with regulatory T cell frequency.Eur J Immunol 35:2157-62.
Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. (2005) Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.Nat Immunol 6:571-8.
Hawlisch H, Wills-Karp M, Karp CL, Kohl J. (2004) The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma.Mol Immunol 41:123-31.
Thio CL, Mosbruger TL, Kaslow RA, Karp CL, Strathdee SA, Vlahov D, O'Brien SJ, Astemborski J, Thomas DL. (2004) Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.J Virol 78:11258-62.
Wysocka M, Montaner LJ, Karp CL. (2005) Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis.J Immunol 174:7398-402.
Karp CL, Cooper AM. (2005) An oily, sustained counter-regulatory response to TB.J Clin Invest 115:1473-6.
Karp CL, Flick LM, Yang R, Uddin J, Petasis NA. (2005) Cystic fibrosis and lipoxins.Prostaglandins Leukot Essent Fatty Acids 73:263-70.
Karp CL, Colebunders R. Approach to the patient with HIV and coinfecting tropical infectious diseases. in Tropical Infectious Diseases: Principles, Pathogens, and Practice, 2ND Edition; ed. Guerrant RL, Walker DH, and Weller PF. Churchill Livingstone, New York. 2005. in press.
Wills-Karp M, Karp CL. (2004) Biomedicine. Eosinophils in asthma: remodeling a tangled tale.Science 305:1726-9.
Wills-Karp M, Karp CL. (2004) Chitin checking--novel insights into asthma.N Engl J Med 351:1455-7.
Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, Belkaid Y, Xu Y, Whitsett JA, Accurso FJ, Wills-Karp M, Petasis NA. (2004) Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.Nat Immunol 5:388-92.
Wills-Karp M, Belkaid Y, Karp CL. (2003) I-Tim-izing the pathways of counter-regulation.Nat Immunol 4:1050-2.
Byrnes AA, McArthur JC, Karp CL. (2002) Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production.Ann Neurol 51:165-74.
Wills-Karp M, Santeliz J, Karp CL. (2001) The germless theory of allergic disease: revisiting the hygiene hypothesis.Nat Rev Immunol 1:69-75.
Byrnes AA, Ma X, Cuomo P, Park K, Wahl L, Wolf SF, Zhou H, Trinchieri G, Karp CL. (2001) Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity.Eur J Immunol 31:2026-34.
Atabani SF, Byrnes AA, Jaye A, Kidd IM, Magnusen AF, Whittle H, Karp CL. (2001) Natural measles causes prolonged suppression of interleukin-12 production.J Infect Dis 184:1-9.
Wysocka M, Robertson S, Riemann H, Caamano J, Hunter C, Mackiewicz A, Montaner LJ, Trinchieri G, Karp CL. (2001) IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness.J Immunol 166:7504-13.
Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Kohl J, Wahl L, Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M. (2000) Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma.Nat Immunol 1:221-6.
Karp CL, Biron CA, Irani DN. (2000) Interferon beta in multiple sclerosis: is IL-12 suppression the key?Immunol Today 21:24-8.
Karp CL, Neva FA. (1999) Tropical infectious diseases in human immunodeficiency virus-infected patients.Clin Infect Dis 28:947-63.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. (1998) Interleukin-13: central mediator of allergic asthma.Science 282:2258-61.
Karp CL, Wysocka M, Ma X, Marovich M, Factor RE, Nutman T, Armant M, Wahl L, Cuomo P, Trinchieri G. (1998) Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance.Eur J Immunol 28:3128-36.
Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE. (1996) Mechanism of suppression of cell-mediated immunity by measles virus.Science 273:228-31.
Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB, Sacks DL. (1993) In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma.J Clin Invest 91:1644-8.